Genflow Biosciences Share Discussion Threads

[steg] 24/5/2024 14:48

New placing Blakesmith? Interesting what makes you think that? Definitely possible, a bit more loot for initial Nash trials in 2025 would help but then it will take a Pharma partner as that’s big money for big scale clinical trials

[moneymunch] 24/5/2024 13:14

Lol :-))))

[blakesmith] 24/5/2024 13:02

New placing

[moneymunch] 24/5/2024 12:03

Right time, right place and just the start of a stellar journey ahead and hoping we have a Major JV partner in the frame who wants in early on Genflow’s cutting edge science and multi-billion dollar potential of Sirt6's potency in the longevity space and multiple disease targets. Gl :-))))

[prashaprash] 24/5/2024 11:32

Soon will cross the opening high! Founder Eric has invested his own 50000£ so tells us the volume of the confidence his biotech!Should hear some update on research before get with human research!Here for atleast 3 years..

[moneymunch] 24/5/2024 11:18

12 month high coming soon!!! Gla holders..On and UP!!! :-)

[moneymunch] 24/5/2024 11:08

Happy Days!!! Genflow is all set for a stellar rise!!! Gla holders:-)

[citys2874] 24/5/2024 10:41

Nice to GENF and CRTM breaking out this morning ....looking like a great Friday

[moneymunch] 24/5/2024 08:34

On and UP!!! Exciting times!!! Gla :-)

[moneymunch] 24/5/2024 07:15

10th - 11th June 2024 - Organised by Longevity Technology who hold 3% of Genflow, the advisory panel includes Eric Verdin who sits on Genflow's Scientific Advisory Board, Aubrey de Grey who originally was a member of Genflow's SAB and Jim Mellon who was an investor in Genflow's IPO....All bodes well!!! Gla ;-)


New international event program launches to bring longevity entrepreneurs and investors together.

Founders Forum and Longevity.Technology today announced the launch of the Founders Longevity Forum, a premier event series designed to educate and connect investors with the vast potential within the longevity market.

The inaugural Founders Longevity Forum will take place at Olympia London during the renowned London Tech Week, focusing on a sector that is projected to exceed $600 billion by 2025. This partnership aims to foster meaningful connections between startups, venture capitalists (VCs), corporate venture capitalists (CVCs), family offices and CEOs leading the charge in longevity.

Brent Hoberman, Co-Founder and Executive Chair of Founders Forum Group, said: “Longevity is becoming a mega trend as science makes increased healthspans more realistic, converging with a wider shift towards preventative healthcare.

“We’ve noticed a need to connect top scientists and innovative startups with funds to help them turn their dreams into reality. By bringing together the best and brightest minds working on longevity today, we can galvanize progress in this area and transform the demographic landscape.”

Taking place on New international event program launches to bring longevity entrepreneurs and investors together.4, the Founders Longevity Forum will address the investment opportunities across the longevity space, from established longevity business models such as diagnostics, longevity clinics and supplements, through to cutting-edge longevity biotech companies poised to revolutionize the biotech industry and transform society.

The event will also benefit from an advisory panel that has decades of longevity and geroscience expertise between them; the panel includes Eric Verdin, Andrea Maier, Jim Mellon and Aubrey de Grey, with further members to be announced.

“Multiple longevity events are happening and they’re all great, but few are specifically focused on bringing more investors into this rapidly accelerating field,” said Phil Newman, Founder and CEO, Longevity.Technology.

“We plan to stage events in London, Abu Dhabi and San Francisco initially to accelerate longevity investment globally, and catalyze a wave of innovation and collaboration that will redefine the future of human health.”

“We’re keen to educate investors on the vast opportunities in longevity whilst fostering meaningful connections for startups and scaleups in this niche,” said Carolyn Dawson, CEO, Founders Forum Group.

“Helping create these connections is central to our mission at Founders Forum Group as we seek to empower entrepreneurs at every stage of their journeys; with Longevity.Technology as our partner, we can forge formative alliances that propel longevity innovation.”

Key highlights of the Founders Longevity Forum:

Exclusive event – The Founders Longevity Forum will host a minimum of 120 approved guests, including high-caliber investors, family offices, longevity founders and VIPs.

Comprehensive program – guests will enjoy a half-day of content, a welcome reception, a full-day program and automatic registration for London Tech Week.

Global reach – following the London event, the Founders Longevity Forum will travel to Abu Dhabi and San Francisco.

Longevity takes center stage – The Longevity Village at London Tech Week will elevate this dynamic industry, showcasing the companies applying new technologies to extend human healthspan.

[moneymunch] 23/5/2024 21:56

Perfectly poised. Gla :-)

[northeast14] 23/5/2024 13:47

Good consolation. Ready for the next leg up!

[moneymunch] 23/5/2024 07:57

We've hit a 6 month high and every chance we'll hit a 12 month high as good news is delivered by Eric and the team. Momentum building, excitement building. Genflow has the potential and prospects to be the stand out share for 2024 and beyond!!! Gla holders:-)

[moneymunch] 21/5/2024 18:25

Genflow Biosciences (LON:GENF) (OTCQB:GENFF)

1,611 followers
5h

At Genflow Biosciences (LON:GENF) (OTCQB:GENFF), our research focuses on the #SIRT6 gene which may hold the key to extending the #healthspan of humans and their canine companions.

A mutation known as "#Centenarian SIRT6" could be crucial for developing new treatments. The following highlights underscore our unique position:

✅ immense global market with few competing treatments
✅ impressive, long life IP for both gene & gene delivery
✅ key clinical and regulatory milestones expected in next 18 months

Learn more about #GENF's cutting edge work here:
An anti ageing research company based in London | Genflow

[moneymunch] 21/5/2024 16:09

The smart Money is accumulating as the free float gets squeezed with the majority of shares held very tightly. Positive newsflow could drop at anytime on multiple fronts including confirmation of the payment of €770k from the €2.89m grant, expected imminently, which should be very well received. Game changing news also possible judging by the re-rate in progress....they want your shares!!! Gla :-)

[northeast14] 20/5/2024 19:51

Show me the Money!

[moneymunch] 20/5/2024 18:28

Given how low the free float must be, it probably takes a whole day to fill such an order, and so the only way is UP from now on in i reckon, and the chart now looks perfectly poised for the next move North, and so fingers crossed for some good news from Eric. Gl ;-)

[northeast14] 20/5/2024 18:04

Looks like a buy too. Are they trying to shake people out with the drops?

[moneymunch] 20/5/2024 17:56

1m buy sneaked in, late reported from Friday. Gla :-)

[moneymunch] 20/5/2024 08:45

Cutting edge science with patents pending, compelling preclinical data progressing to human clinical trials, prestigious academic partners and a leading influential and distinguished hands on Scientific Advisory Board.

Exponential upside potential and prospects!!! Gla :-)

[moneymunch] 19/5/2024 20:14

This coming week could be exciting imho, continued UPward momentum very likely as the next UPdate on proceedings gets closer. Game changing news at anytime on clinical progress, US institutional investors, JV partner and or additional grant funding from the likes of the Hevolution Foundation, the Saudi organisation who have an annual $1 billion dollar investment fund into the longevity space, who appear to have close links to Eirc Verdin, a highly respected and leading scientist who sits on Genflow’s Scientific Advisory Board. Hevolution invested $20m into the Buck Institute end of last year, where Eric Verdin is the CEO and invested a further $20m last month into Aeovian, who just so happen to be founded by the Buck Institute. Hopefully the share accumulation that's been in progress are by those who know more than us and yet are just as excited by the enormous potential ahead. Gla :-)



.....

18th May 2024

[steg] 17/5/2024 17:02

Yes they are and hopefully filled at a higher price next week, can’t believe anyone would sell just now when it’s genuinely a screaming buy GLA

[moneymunch] 17/5/2024 15:40

Big buys being filled!!!??? Gla :-)

[moneymunch] 17/5/2024 08:24

Another big day on the cards Northeast, with any luck. The majority of shares are now very tightly held for better and bigger things to come, and so plenty of UPside momentum from now on in, from those who want in, including the bigger players who are accumulating for the significant re-rate ahead!!! Gl :-)

[moneymunch] 17/5/2024 07:22

The Business Case for Longevity

·May 2024 ·

Longevity is the biggest market in the world.

The ROI is huge, almost too big to see. Many people also don’t realize that longevity businesses are critical for the future of humanity.

Imagine not being resigned to growing old, frail and sick. Imagine being able to extend your peak earning years. Imagine being able to delay having kids safely (if you choose!) to allow yourself more time to pursue a career. People could have second or third careers. People could invest their money over longer periods of time, accumulating more wealth. People could have the opportunity to actually enjoy that wealth before they die.

If we can extend the human healthspan, it will not just save tons of money (think of all the money dedicated to playing whack-a-mole with age-related diseases). It will also make almost every other industry bigger.

From a business perspective, this all increases the “L” in LTV (lifetime value of customers). More people living longer, more fulfilled lives has the potential to increase returns across many industries, and will probably create new ones over time. The TAM for Longevity is everyone.

Society has a choice: spend trillions on early death, or make trillions in longer life.

Reason 1: The Market is Everyone

Drug companies make money when there’s a lot of demand for their drug (lots of sick people), or there are limited treatment options available (only drug in town). But the best bet is to go for the big market. As a result, most of the blockbusters come from pursuing diseases that affect nearly everyone eventually.

For example, the top ten leading causes of death in the US are:

Heart Disease
Cancer
Accidents
Cerebrovascular disease
Chronic lower respiratory disease
Alzheimer’s
Diabetes
Kidney Disease
Liver Disease
COVID-19

In turn, some of the top-selling drugs include:

Lipitor, one of the best selling drugs of all time, is a cholesterol drug intended to help prevent heart disease – the #1 cause of death in the US.

Keytruda, for treating multiple cancers, is projected to be the 2nd best selling drug by 2028.

GLP-1 Drugs, like Ozempic, which treat both diabetes and aid with weight loss (a risk factor for many of these causes of death) are projected to be among the best sellers of all time.

Addressing just one of the leading causes of death in the US is enough to make a blockbuster drug. Addressing all of them at once is the biggest blockbuster of all time. And that’s what longevity medicines can do.

When we break down the top ten cases of death, you can see that aging is a primary risk factor for most of them. Between the ages of 1 and 44, the thing most likely to kill you is an unintentional injury (wear your seat belts). But past that point, heart disease, cancer, and COVID are the biggest threats. (Remember COVID is typically harmless to younger people, but is dangerous for people over 45).

Treating aging would be like addressing the heart disease, COVID, cancer, and diabetes markets all at once. It’s like a prophylactic for dying from preventable causes. And who wouldn’t like to take that drug? Nobody.

That’s mega-blockbuster potential.